Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Apr;32(4):426–429. doi: 10.1128/aac.32.4.426

Randomized comparative study of 0.5 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea.

A H van der Willigen 1, J H Wagenvoort 1, W O Schalla 1, J S Knapp 1, J M Boot 1, P L Heeres-Weststrate 1, M F Michel 1, B van Klingeren 1, E Stolz 1
PMCID: PMC172194  PMID: 3377456

Abstract

Uncomplicated urogenital and concomitant oropharyngeal gonorrhea in 424 male and female patients was treated in a randomized comparative study with 0.5 g of cefodizime (89 men and 54 women), 1 g of cefodizime (87 men and 52 women), or 1 g of cefotaxime (86 men and 56 women). The cure rates were 100% for men and women in the group given 0.5 g of cefodizime, 100% for men and women in the group given 1 g of cefodizime, and 99% for men and 100% for women in the group given 1 g of cefotaxime. The MICs of cefodizime and cefotaxime for the isolate of Neisseria gonorrhoeae ranged from 0.004 to 0.06 micrograms/ml. Chlamydia trachomatis was isolated before treatment in 15% and after treatment in 13% of all patients. Side effects, such as nausea, diarrhea, abdominal pain, genital candidiasis, and pain at the site of injection, developed in 4% of the patients given cefodizime. Side effects, such as vertigo, genital candidiasis, fatigability, and diarrhea, developed in 4% of the patients treated with cefotaxime. In both groups of patients, the side effects were mild and transient. Cefodizime and cefotaxime are safe and effective agents in the treatment of uncomplicated urogenital gonorrhea.

Full text

PDF
426

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aardoom H. A., de Hoop D., Iserief C. O., Michel M. F., Stolz E. Detection of Neisseria gonorrhoeae antigen by a solid-phase enzyme immunoassay. Br J Vener Dis. 1982 Dec;58(6):359–362. doi: 10.1136/sti.58.6.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ansink-Schipper M. C., Huikeshoven M. H., Woudstra R. K., van Klingeren B., de Koning G. A., Tio D., Schoonhoven F. J., Coutinho R. A. Epidemiology of PPNG infections in Amsterdam: analysis by auxanographic typing and plasmid characterisation. Br J Vener Dis. 1984 Feb;60(1):23–28. doi: 10.1136/sti.60.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Khan M. Y., Gruninger R. P., Nelson S. M., Obaid S. R. Comparative in vitro activity of cefodizime, ceftazidime, aztreonam, and other selected antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1983 Mar;23(3):477–478. doi: 10.1128/aac.23.3.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Schalla W. O., Whittington W. L., Rice R. J., Larsen S. A. Epidemiological characterization of Neisseria gonorrhoeae by lectins. J Clin Microbiol. 1985 Sep;22(3):379–382. doi: 10.1128/jcm.22.3.379-382.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Scully B. E., Jules K., Neu H. C. In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin. Antimicrob Agents Chemother. 1983 Jun;23(6):907–913. doi: 10.1128/aac.23.6.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Stamm W. E., Tam M., Koester M., Cles L. Detection of Chlamydia trachomatis inclusions in Mccoy cell cultures with fluorescein-conjugated monoclonal antibodies. J Clin Microbiol. 1983 Apr;17(4):666–668. doi: 10.1128/jcm.17.4.666-668.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Stolz E., Ong L., van Joost T., Michel M. F. Treatment of non-complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):295–299. doi: 10.1093/jac/14.suppl_b.295. [DOI] [PubMed] [Google Scholar]
  9. Stolz E., Zwart H. G., Michel M. F. Sensitivity to ampicillin, penicillin, and tetracyline of gonococci in Rotterdam. Br J Vener Dis. 1974 Jun;50(3):202–207. doi: 10.1136/sti.50.3.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Tegelberg-Stassen M. J., van der Hoek J. C., Mooi L., Wagenvoort J. H., van Joost T., Michel M. F., Stolz E. Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin. Eur J Clin Microbiol. 1986 Apr;5(2):244–246. doi: 10.1007/BF02013999. [DOI] [PubMed] [Google Scholar]
  11. Tegelberg-Stassen M. J., van der Willigen A. H., van der Hoek J. C., Wagenvoort J. H., van Vliet H. J., van Klingeren B., van Joost T., Michel M. F., Stolz E. Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin. Eur J Clin Microbiol. 1986 Aug;5(4):395–398. doi: 10.1007/BF02075693. [DOI] [PubMed] [Google Scholar]
  12. van der Willigen A. H., van der Hoek J. C., Wagenvoort J. H., van Vliet H. J., van Klingeren B., Schalla W. O., Knapp J. S., van Joost T., Michel M. F., Stolz E. Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrob Agents Chemother. 1987 Apr;31(4):535–538. doi: 10.1128/aac.31.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES